LONE TREE, Colo., December 21, 2015 /ACCESSWIRE/ — Zynex (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurodiagnostic equipment, cardiac and blood volume monitoring, announced today that it has appointed Deltason Medical as its distributor in Taiwan for its NeuroMove(TM) product line.

CEO, Thomas Sandgaard, said: “We have done business with Deltason in Hong Kong and China for several years and have been very impressed by their professionalism and their ability to promote our NeuroMove devices. We agreed to expand their territory to also include Taiwan and Macau.”

The NeuroMove(TM) is a FDA cleared device for Stroke Rehab that has been proven effective in many clinical studies. The NeuroMove technique assists patients in teaching healthy parts of the brain after a stroke to take over lost functionality through Neuroplasticity. Many stroke and spinal cord injured patients in the US and abroad have experienced dramatic results with the device. NeuroMove works by detecting the attempts to move a muscle group sent from the brain, combining muscle contraction, visual and sensory feedback to assist the patient with relearning the movement.

About Zynex

Zynex, founded in 1996, markets and sells its own design of electrotherapy medical devices used for pain management and rehabilitation; and the company’s proprietary NeuroMove device designed to help recovery of stroke and spinal cord injury patients. Zynex is also developing a new blood volume monitor for use in hospitals and surgery centers. For additional information, please visit: Zynex.com.

Safe Harbor Statement

Certain statements in this release are “forward-looking” and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain additional capital or augment our liquidity in order to continue our business, the success of our compound pharmacy and international expansion efforts, our ability to engage additional sales representatives, the success of such additional sales representatives, the need to obtain FDA clearance and CE marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement from insurance companies for products sold or rented to our customers, acceptance of our products by health insurance providers, our dependence on third party manufacturers to produce our goods on time and to our specifications, implementation of our sales strategy including a strong direct sales force, the uncertain outcome of pending material litigation and other risks described in our filings with the Securities and Exchange Commission including the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2014.

Contact:
Zynex, Inc.
(303) 703-4906

SOURCE Zynex